Investor Forum, 25th January 2017: Kromek, Ergomed & Realm Therapeutics
We will be hosting our next Investor Forum at Fladgate (please note the new venue) on the evening of Wednesday 25th of January 2017 and are delighted to invite you to attend and meet the management of Kromek, Ergomed and Realm Therapeutics (formerly PuriCore).
Kromek Group plc (KMK)
Kromek is a leading developer of radiation detection solutions based on high performance sensor materials, primarily cadmium zinc telluride (CZT), for applications within the medical, nuclear and security screening markets. Kromek’s solutions provide high resolution information on material composition and structure to enable the identification of cancerous tissues and hazardous materials (including explosives), and the analysis of radioactive materials.
Dr Arnab Basu, CEO, will represent the company.
Ergomed plc (ERGO)
Ergomed is a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. It operates globally in over 40 countries. Ergomed plc has two complementary businesses: (1) The Services Business – a well-established, clinical research business providing services to the pharmaceutical and biotechnology industry; and (2) The Co-Development Business – a growing portfolio of partnerships with pharmaceutical and biotech companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including outlicensing milestones as well as sales of the product.
Stephen Stamp, Chief Finance Officer, will represent the company.
Realm Therapeutics plc (formerly PuriCore) (RLM)
Realm Therapeutics is a biopharmaceutical company passionately committed to leveraging its proprietary technologies to protect and improve the health of adults and children. The Company’s drug development focus, utilizing its immunomodulatory formulations, is targeted initially on developing small molecule therapies in inflammatory diseases with potential application in dermatology and ophthalmology, and the potential for broad applicability across a number of other diseases.
Alex Martin, Chief Executive Officer, will represent the company.
New Venue: Fladgate LLP, 16 Great Queen Street, London, WC2B 5DG
Time: 5.00pm for a prompt 5.30pm start, 35 mins for each company to present and answer questions, and drinks and canapés to follow at 7.15pm.
Date: Wednesday 25th of January 2017
Please contact: email@example.com with any questions.